Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…
Drug updates
Recent Posts
- Next-generation therapy may help babies with Pompe live longer, better
- I wonder about the questions my daughter hasn’t asked me yet
- TRPML1 activation may boost Pompe ERT effects in new cell study
- How a mother helps her daughter face Pompe disease treatment
- Muscle MRI may detect early changes in late-onset Pompe disease